FDA Looks to Canada for Marijuana Regulation Advice
The U.S. Food and Drug Administration (FDA) is taking interest in how to effectively regulate marijuana.
The agency is cohosting a conference later this month that will include a panel examining Canada’s system of legal medical cannabis, according to a notice published in the Federal Register on Thursday.
The session, led by Chris Rose, director of operations for Canadian government’s Office of Medical Cannabis, “will provide an overview of current regulatory framework for the regulation of marijuana for medical purposes in Canada and include information on the licensing process, compliance and enforcement and market statistics,” the conference’s website says.
The news comes in the wake of reports the Drug Enforcement Administration (DEA) will soon to act on a marijuana rescheduling recommendation it received from FDA. It is not yet publicly known whether the health agency recommended a change in the drug’s classification or if it weighed in for keeping marijuana in Schedule I of the Controlled Substances...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin